Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer
Cancer Medicine · 2025
DOI: 10.1002/cam4.71114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Donghyun Kim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Colorectal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Mutational landscape is prognostic in colorectal cancer (CRC). Rat sarcoma ( RAS ) oncogenes, such as KRAS and NRAS , with driver mutations, portend poor survival outcomes, whereas pathologic mutations in HRAS are extremely rare, and their prognostic value remains uncertain.
Methods
This retrospective study analyzed the Oncology Research Information Exchange Network (ORIEN) alliance tumor RNA‐Seq data in Stages II and III CRC to investigate the association between RAS gene expression and survival outcomes.
Results
High transcript levels of HRAS were associated with superior overall survival (OS). The high HRAS ‐associated OS benefit was most pronounced in patients with right‐sided primary expressing low KRAS transcript levels in the absence of pathologic KRAS mutations.
Conclusions
Contrary to the notion that RAS family genes are proto‐oncogenic, this study demonstrates that high HRAS transcript levels are associated with superior OS in Stages II and III CRC. The potential of HRAS as a prognostic biomarker should be explored further.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
- Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA.
- Department of Surgery, University of Kentucky, Lexington, Kentucky, USA.
- Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
- Department of Clinical & Life Sciences, Aster Insights, Hudson, Florida, USA.
- Section of Hematology-Oncology, Department of Internal Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
ORCID-Profile: Donghyun Kim, Patrick M Boland, Lyen C Huang
Förderung
- NCI NIH HHS
Zitieren
APA
Kim, D., Sharif, S., Garay, J. A. R., Bhakta, A. S., Boland, P. M., Cavnar, M. J., Churchman, M. L., Hatoum, H., Huang, L. C., Kim, J., Kim, R., Lentz, R. W., Mukherjee, S., O'Donnell, M. T., Quartey, B., Reilley, M. J., Rounbehler, R. J., Salhia, B., Schneider, B. P., & Chan, C. H. (2025). Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71114
Vancouver
Kim D, Sharif S, Garay JAR, Bhakta AS, Boland PM, Cavnar MJ, et al. Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.71114
BibTeX
@article{Kim2025,
author = {Kim, Donghyun and Sharif, Saima and Garay, Juan Antonio Raygoza and Bhakta, Avanish S and Boland, Patrick M and Cavnar, Michael J and Churchman, Michelle L and Hatoum, Hassan and Huang, Lyen C and Kim, Joseph and Kim, Richard and Lentz, Robert W and Mukherjee, Sarbajit and O'Donnell, Mary T and Quartey, Benjamin and Reilley, Matthew J and Rounbehler, Robert J and Salhia, Bodour and Schneider, Bryan P and Chan, Carlos H},
title = {Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71114}
}
EUVIMED